Wednesday, June 4, 2025
28.4
C
Bengaluru
My account
Get into your account.
Hot topics
Boehringer Ingelheim India focuses on partnerships in NCD management
Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”
IMS Health Market Reflection Report for July 2016
The Indian Pharmaceutical Market (IPM) was valued atRs. 10,025 crores in the month of July 2016 clocking a 14.7% growth over same period last year (SPLY). This was the first time ever the market crossed the 10,000 crore mark in a single month.
Dr. Peter Velev, CEO of CredoWeb discussing Digital in Pharma with MedicinMan
The digital revolution is the fourth industrial revolution. It changes models, processes and whole public sectors. In many reports you will find that, in terms of digitalization, pharma is just next to the public sector, as least digitalized. Pharma just started late. There are many reasons for that – it is one of the most regulated industries with lots of sensitive data involved and many ethical aspects. But the slowed down digitalization has a lot to do with some subjective reasons. Adopting digital technologies requires changing existing models which requires a different mindset – and this is difficult to achieve. Nowadays, in the situation of a global pandemic, we see that digital communication is not only necessary to be successful but it is a must in order to adapt to the New Normality.
72nd Republic Day: What’s the Road Ahead for Indian Pharma?
“We are getting too happy, for too little”: these...
Is Your Field Force Optimised to Make the Most of Market Growth in Metros?
Summary of Performance of Top 30 Metros in IPM...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Hot topics
IQVIA Sponsors Race for 7 to Commemorate World Rare Disease Day
“IQVIA is delighted to be associated for the fourth consecutive year as the main sponsor of Race for 7. While rare diseases, by virtue of their definition, affect relatively fewer number of patients, the overall number of rare disease patients is large enough to warrant more focused attention."
The ‘Amazonization’ of Healthcare
Inside this Issue
1. The 'Amazonization' of Healthcare by Salil Kallianpur
Amazon's drive...
Are Digital Pharmacies a Game Changer?
Lower prices, discounts, convenience of ordering and home delivery are some of the benefits for consumers with e-pharmacies. The anonymity of the internet encourages patients to seek information about medicines that they would otherwise avoid. Mental health is one area where the consumers wish to maintain confidentiality and opt for online consultation and medication.
Making Peace with an Unlived Life – My Journey by Deep Bhandari
The Beginning
I was at crossroads after completing computer...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Newsletter
Get important news delivered directly to your inbox and stay connected!